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Abstract
Background Quality of life (QoL) is one of the most sig-
nificant issues in prostate cancer treatment decisions. This
study aimed to investigate the toxicity of hypofractionated
stereotactic radiotherapy (SBRT) and QoL after treatment
in localized prostate cancer patients.
Materials and methods A prospective single-center clinical
study was performed in low- and intermediate-risk prostate
cancer patients. Patients received 33.5 Gy in 5 fractions
(SHARP regimen). Acute and late toxicity was assessed ac-
cording to RTOG/EORTC score. Patients filled out EORTC
QLQ-C30 and prostate cancer-specific QLQ-PR25 ques-
tionnaires.
Results The analysis included 68 prostate cancer pa-
tients (55–83 years, median 73) with clinical stage T1c-
T2cN0M0, median combined Gleason score of 6 (3–8), and
median prostate-specific antigen (PSA) level of 10 ng/mL
(4–20 ng/mL). Neoadjuvant androgen deprivation therapy
was given to 52 patients (76.5 %), and stopped in 31 pa-
tients (45.5 %) after 6 months; in 21 patients (31 %) after
2–3 years. Average and median follow-up was 24 months
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(18–45). Median nadir PSA level was 0.03 ng/mL for
all patients and 0.6 ng/mL for patients without hormone
treatment. No patients had PSA failure. There were no
acute grade IV toxicities. One patient (1.5 %) developed
grade III and 24 patients (35.3 %) grade II acute blad-
der toxicity. No one developed grade III and 7 patients
(10.3 %) grade II acute rectal toxicity. No grade III or
IV late gastrointestinal or genitourinary toxicities were
reported. Grade II late urinary symptoms were observed
in 8 patients (11.8 %) and gastrointestinal symptoms in
3 patients (4.4 %). Global health status/QoL was good and
improved during the observational period.
Conclusion SBRT for prostate cancer patients is a well-
tolerated treatment in terms of toxicity and QoL, has no
negative impact on functioning and everyday life, with the
important benefit of a short treatment period. However,
long-term follow-up data are needed.
Keywords Hypofractionated stereotactic radiotherapy ·
Quality of Life · Rectum · Bladder · Organs of risk
Hypofraktionierte stereotaktische Radiotherapie
SHARP ist eine gut tolerierte Behandlung beim
Prostatakarzinom
Beurteilung der Toxizität und Lebensqualität
Zusammenfassung
Hintergrund Die Lebensqualität (QoL) ist zu einem der
wichtigsten Schwerpunkte bei der Wahl der Prostatakarzi-
nombehandlung geworden. Das Thema dieser Studie war
die Untersuchung der Toxizität der hypofraktionierten ste-
reotaktischen Radiotherapie (SBRT) und der QoL nach Be-
handlung des lokal begrenzten Prostatakarzinoms.
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Materialien und Methoden Die prospektive, monozentri-
sche, klinische Studie wurde bei Prostatakarzinompatien-
ten mit niedrigem bis mittlerem Risiko durchgeführt. Die
Patienten erhielten 33,5 Gy in 5 Fraktionen (SHARP-Be-
handlungsschema). Akute und späte Toxizität wurden nach
den Kriterien des RTOG/EORTC-Scores klassifiziert. Die
Patienten füllten das EORTC-QLQ-C30- und das prosta-
takarzinomspezifische QLQ-PR25-Formular aus.
Ergebnisse Die Analyse umfasste 68 Prostatakarzinompa-
tienten (medianes Alter 73, Spanne 55–83 Jahre) im klini-
schen Staging T1c–T2cN0M0, mit einem medianen Glea-
son-Score von 6 (Spanne 3–8) und einem medianen PSA-
Wert (prostataspezifisches Antigen) von 10 ng/ml (Spanne
4–20 ng/ml). Eine neoadjuvante Androgendeprivationsthe-
rapie erhielten 52 Patienten (76,5 %); die Hormontherapie
beendet 31 Patienten (45,5 %) nach 6 Monaten und 21 Pa-
tienten (31 %) nach 2–3 Jahren. Das durchschnittliche und
mediane Follow-up dauerte 24 Monate (Spanne 18–45).
Der mediane PSA-Nadir betrug 0,03 ng/ml für alle Pati-
enten und 0,6 ng/ml für Patienten ohne Hormontherapie.
PSA-Versagen und akute Grad-IV-Toxizitäten traten nicht
auf. Ein Patient (1,5 %) hatte eine Grad-III- und 24 Patien-
ten (35,3 %) eine Grad-II-Harnblasentoxizität, kein Patient
eine Grad-III- und 7 Patienten (10,3 %) eine akute Grad-
II-Rektumtoxizität. Späte gastrointestinale oder urogenita-
le Toxizitäten III. oder IV. Grades wurden nicht berichtet.
Bei 8 Patienten (11,8 %) traten späte Miktionsbeschwer-
den II. Grades und bei 3 Patienten (4,4 %) gastrointestinale
Symptome auf. Globaler Gesundheitsstatus/QoL war gut
und besserte sich in der untersuchten Zeit.
Schlussfolgerung SBRT ist beim Prostatakarzinom eine gut
tolerierte Behandlung hinsichtlich Toxizität und QoL, ohne
negativen Einfluss auf das Alltagsleben und dem wichtigen
Vorteil einer kurzen Behandlungszeit. Langfristige Follow-
up-Untersuchungen müssen noch folgen.
Schlüsselwörter Hypofraktionierte stereotaktische
Radiotherapie · Lebensqualität · Rektum · Harnblase ·
Risikoorgane
Prostate cancer is the second most common solid tumor in
men worldwide [1]. The standard treatment for early-stage
prostate cancer is surgery or radiotherapy. Radical prosta-
tectomy is an option for men with a life expectancy of
at least 10 years. Radiotherapy is a reasonable alternative
to surgery. Observational data and retrospective analyses
suggest that the results of surgical treatment and radiation
therapy are similar in patients with localized prostate can-
cer. The disease-specific survival rate is 98 % for patients
after radical prostatectomy and 97 % for patients after ex-
ternal beam radiotherapy (p = 0.543) [2]. In the case of
clinically localized, very low- and low-risk prostate cancer,
active surveillance (“wait and see”) is also an option.
The goal of radiotherapy is to deliver an adequate dose
of radiation to the target, in this case the prostate, with
an appropriate margin and while minimizing the dose to
normal tissues (in the rectum, bladder, bulb of penis, and
femoral heads). Three-dimensional conformal radiation
therapy (3D-CRT) has replaced the old two-dimensional
technique and has been the standard treatment for prostate
cancer patients for years. Dose escalation with intensity-
modulated radiation therapy (IMRT) resulted in improved
cancer control in comparison to 3D-CRT, without increased
toxicity [3]. IMRT has now been established as the stan-
dard external beam modality in low-risk prostate cancer
[4–6]. Image-guided radiotherapy (IGRT) is used to reduce
the volume of irradiated normal tissue [7, 8]. Recent data
suggest that hypofractionated radiotherapy (2.5–3.1 Gy per
fraction) results in high local control of prostate cancer with
acceptable toxicity [9–11]. Stereotactic body radiation ther-
apy (SBRT) is an extreme form of hypofractionation that
uses several high-dose fractions (6–7 Gy). The first pub-
lications on hypofractionation in the treatment of prostate
cancer patients came out in the early 1990s [12, 13]. For
intermediate-risk patients, androgen deprivation therapy is
recommended, and should start 6 months before external
beam radiotherapy [14].
The prognosis for most prostate cancer patients, partic-
ularly those in an early stage and independent of treatment
options, is very good. For prostate cancer survivors, quality
of life (QoL) is a very important factor and it has become
one of the most significant issues in prostate cancer treat-
ment decisions.
The objective of this study was to investigate the effec-
tiveness and safety of hypofractionated SBRT for localized
prostate cancer, as well as patients’ QoL after treatment.
Materials and methods
A prospective single-center clinical study was performed in
low- and intermediate-risk localized prostate cancer patients
(according to the National Comprehensive Cancer Network,
NCCN). All patients underwent thoracic X-ray, abdomi-
nal ultrasonography, pelvic magnetic resonance (MR), and
bone scintigraphy.
Treatment planning
Patients were treated according to the special protocol pre-
pared for this study. Patients were placed on a diet designed
to minimize gas production, without milk products, fresh
fruits, and vegetables, 14 days before planning and during
the entire treatment period. We used three fiducial markers
(soft tissue gold markers; Civco, Coralville, IA, USA) for
daily image-guided positioning. The patients were in the
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Tab. 1 Patients’ characteristics
Number (total N = 68) %
Age (years) 55–83 (median 73, mean 72.5)
≤ 65 10 15












PSA (ng/mL) 4–20 (median 10, mean 10.9)
≤ 10 35 51






6 months 31 45.5
2–3 years 21 31
PSA prostate-specific antigen
supine position, immobilized by a vacuum mattress (Blue-
BAG; Medical Intelligence, Klongtoey, Bangkok), and were
set up with four tattoos. Computed tomography (CT) and
MR images (acquired at least 14 days after fiducial place-
ment) were used in treatment planning. Slice thicknesses
for planning were 1.5 mm for CT and 3 mm for MRI. Plan-
ning (and treatment) was carried out with a filled bladder
(200–300 mL) and empty rectum. According to Interna-
tional Commission on Radiation Units and Measurements
(ICRU) reports 50 and 62 [15, 16], the clinical target vol-
ume (CTV) included the prostate and the proximal part of
the seminal vesicles (about 1 cm) with a margin of 3 mm
(2 mm from the rectum), and the planning target volume
(PTV) was equal to the CTV but expanded by a 2 mm
isotropic margin. Step-and-shoot IMRT plans were made.
According to ICRU report 83 [17], 95 % of the PTV should
receive at least 98 % of the prescription dose.
Treatment
All patients were treated with 15-MV X-rays using a Primus
accelerator (Siemens, Berlin, Germany). The positions of
the prostate, rectum, and bladder were visualized daily with
MV cone beam CT and portal images. The volumes of rec-
tum and bladder were checked and corrected if necessary.
There were daily positioning corrections of the patient with
reference to position of the markers. It was necessary to
avoid underdosage in the PTV and too high doses to organs
of risk [18]. The patients received 33.5 Gy in 5 fractions
(6.7 Gy per fraction), similarly to those enrolled in the
stereotactic hypofractionated accurate radiotherapy of the
prostate (SHARP) trial [19]. Patients were treated twice
weekly for a median of 15 days. The radiation dose of
33.5 Gy in 5 fractions was equivalent to the conventional
dose of 78 Gy in 39 fractions of 2 Gy each; the α/β ratio for
prostate cancer was estimated to be around 1.4–1.5 Gy [9,
20, 21]. The α/β ratio for acute effects in the bladder and
rectum is about 10 Gy; thus, the acute effects equivalent
dose in this hypofractionated regimen was 46.6 Gy. The
α/β ratio for late complications in the rectum is 3 Gy [22].
Taking this into account, the late rectal reactions dose was
equivalent to the dose of 65 Gy in 2-Gy fraction regimens.
Follow-up
Prostate-specific antigen (PSA) levels were obtained before
treatment and every 3 months. Eventual failure was defined
K
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Tab. 2 Acute and late gastrointestinal and genitourinary toxicities according to RTOG/EORTC score
Genitourinary toxicities Gastrointestinal toxicities
Number % Number %
Acute toxicities
0 21 30.9 43 63.2
Grade I 22 32.3 18 26.5
Grade II 24 35.3 7 10.3
Grade III 1 1.5 0 0
Grade IV 0 0 0 0
Late toxicities
0 32 47 53 78
Grade I 28 41.2 12 17.6
Grade II 8 11.8 3 4.4
Grade III 0 0 0 0
Grade IV 0 0 0 0
RTOG/EORTC Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer
as nadir plus 2 ng/mL according to the Phoenix definition
of PSA failure [23, 24].
Acute and late toxicity assessments according to the
Radiation Therapy Oncology Group and the European Or-
ganization for Research and Treatment of Cancer (RTOG/
EORTC) score were carried out during radiotherapy, 1 and
3 months after the end of treatment, and then every
3 months. QoL evaluations were done thrice: at least
9 months after radiotherapy and then every 9 months. The
patients filled out the EORTC QLQ-C30 and the prostate
cancer-specific QLQ-PR25 questionnaires.
The study protocol was approved by the local ethics re-
view board of the University of Warmia and Mazury in
Olsztyn, Poland. All patients submitted a signed consent
form.
We used demographic frequencies and descriptive statis-
tics in the analysis, as well as a Students’ t-test and a general
linear model to measure the mean differences between time
assessments.
Results
Patients were considered eligible for inclusion in this
study if they had previously untreated, histologically con-
firmed adenocarcinoma of the prostate. The analysis
included 68 men (age 55–83 years, mean 72.5 years, me-
dian 73 years) treated between August 2011 and Septem-
ber 2013 at the Department of Radiation Oncology of the
Independent Public Health Care Facility of the Ministry
of the Interior with Warmia and Mazury Oncology Centre
in Olsztyn, Poland. The clinical stage of prostate cancer
was T1c-T2cN0M0, the combined Gleason score was 3–8
(mean and median 6), PSA level was 4–20 ng/mL (mean
10.9 ng/mL, median 10 ng/mL). Neoadjuvant androgen de-
privation therapy beginning a maximum of 6 months before
radiotherapy was given to 52 patients (76.5 %). Hormonal
therapy was stopped after 6 months in 31 patients (45.5 %).
For 21 patients (31 %), androgen blockade was planned
for 2 to 3 years; this was stopped during follow-up in all
patients except two. Of the patients who did not receive
androgen deprivation therapy, 16 (23.5 %) had a median
pretreatment PSA level of 7.53 ng/mL (mean 8.55 ng/mL;
Tab. 1).
Preparation for radiotherapy, according to the protocol
prepared for this study, did not cause a problem for the
patients. The daily setup took approximately 50 minutes;
radiotherapy was delivered in about 6 minutes per fraction.
All patients completed the treatment. The average and
median follow-up was 24 months. The follow-up was
stopped after 9 months for one patient and after 12 months
for another because of other illnesses; all other patients had
a follow-up visit at least 18 months after the end of treat-
ment. No patients died during the observation period. One
patient developed sigmoid colon cancer 24 months after the
end of radiotherapy.
The PSA response was favorable. The median 3-month
posttreatment PSA levels were 0.08 ng/mL for all patients
and 2.8 ng/mL for those who did not receive androgen
deprivation therapy. Twelve months after the end of radio-
therapy, the median PSA levels were 0.06 ng/mL for all
patients, 1.6 ng/mL for those who did not receive androgen
deprivation therapy, and 0.04 ng/mL for patients who un-
derwent 6 months of hormone therapy. Twenty-four months
after the end of radiotherapy, the median PSA levels were
0.1 ng/mL for all patients, 0.4 ng/mL for those who did
not receive androgen deprivation therapy, and 0.1 ng/mL
for patients who underwent 6 months of hormone ther-
apy. The median nadir PSA levels were 0.03 ng/mL
(mean 0.22 ng/mL) for all patients and 0.6 ng/mL (mean
K
Strahlenther Onkol (2016) 192:449–457 453
Fig. 1 Acute and late gastrointestinal (a) and genitourinary (b) toxicities according to Radiation Therapy Oncology Group/European Organization
for Research and Treatment of Cancer (RTOG/EORTC) score
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Fig. 2 Mean results of quality
of life functional scales (a) and
assessment of symptoms (b)
in three measuring points of
observation (in median 9, 21
and 30 months after end of
radiotherapy). a Scale I (left
site) presents subscales of QoL:
physical functioning, emotional
functioning, cognitive function-
ing, role functioning and social
functioning; scale II (right site)
presents summary results for
all functional scales. Lower
results indicate better function-
ing. b Scale I (left site) presents
subscales of each symptoms:
fatigue, nausea and vomiting,
pain, dyspnea, insomnia, loss of
appetite, constipation, diarrhea,
financial difficulties; scale II
(right site) presents summary
results for all symptoms. Lower
results indicate fewer symptoms
0.7 ng/mL) for patients without hormone treatment. At the
median 24-month follow-up, there were no patients with
PSA failure (nadir plus 2 ng/mL). After 6 months of andro-
gen deprivation, the PSA level of two patients increased by
over 1 ng/mL from the nadir during the observation period.
More than two thirds of the patients (75 %) showed stable
or decreased levels of PSA.
Patients’ tolerance of the treatment was good. There
were no acute grade IV toxicities. Most of the patients
(67.6 %) developed mild and moderate (grade I or II) acute
genitourinary and/or gastrointestinal toxicities: 24 patients
(35.3 %) developed grade II acute bladder toxicity and 7 pa-
tients (10.3 %) grade II acute rectum toxicity. Only one
patient (1.5 %) had grade III genitourinary toxicities; no
patients demonstrated grade III acute gastrointestinal toxic-
ities. No grade III or higher late genitourinary or gastroin-
testinal or toxicities were reported. More than one third
of all patients (38 %) did not develop any late radiation-
related complications. More than 3 months after radiother-
apy, 8 patients (11.8 %) had moderate (grade II) urinary
symptoms. No urinary incontinence was observed. Only
3 patients (4.4 %) presented moderate (grade II) gastroin-
testinal symptoms more than 3 months after the treatment
had ended (Tab. 2, Fig. 1).
Evaluations of QoL were done thrice: at 9 months after
radiotherapy, T1 for all patients except 2 (because of dif-
ficulty in coming for evaluation due to other diseases); at
21 months after the end of radiotherapy (63 patients), T2;
and at 30 months after the end of radiotherapy (23 patients),
T3. The global health status (GHS)/QoL improved during
the observational period (mean, M; median, Me; standard
deviation, SD): MQoL1 = 10.09 (N = 66; MeQoL1 = 10.00;
SD = 1.44), MQoL2 = 10.51 (N = 63; MeQoL2 = 10.00;
SD = 1.70), and MQoL3 = 11.30 (N = 23; MeQoL3 =
12.00; SD = 1.18), 9, 21 and 30 months after radiotherapy,
respectively. The biggest functional issues for prostate can-
cer patients were physical and emotional functioning. In
turn, the dominant symptom was fatigue, which decreased
during the observation period (Fig. 2). We observed sig-
nificant or close to significant effects at three measurement
points for specific functional subscales of QoL and gen-
eral symptoms connected with cancer and oncologic treat-
ment: physical functioning (F[2.44] = 3.731; p < 0.05;
eta2 = 0.145), emotional functioning (F[2.44] = 3.074; p =
0.056; eta2 = 0.123), cognitive functioning (F[2.44] = 5.714
with Greenhouse-Geisser correction, GGc; p < 0.01; eta2 =
0.206), social functioning (F[2.44] = 2.997 with GGc; p =
0.068; eta2 = 0.120), and general functional QoL (F[2.44] =
K
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Tab. 3 Pairwise comparison between specific quality of life (QoL) subscales at T1, T2, and T3 measures (only significant or close to significant
effects are presented)
1st factor at specific time 2nd factor at specific time Mean difference SD P-value 95 % CI for mean difference
Lower limit Upper limit
Physical functioning T3 Physical functioning T1 –1.130* 0.418 0.039 –2.212 –0.049
Physical functioning T2 –1.000* 0.367 0.036 –1.947 –0.053
Emotional functioning T1 Emotional functioning T2 –0.522* 0.176 0.022 –0.977 –0.066
Emotional functioning T3 0.087 0.288 0.987 –0.656 0.830
Cognitive functioning T3 Cognitive functioning T1 –0.478* 0.152 0.014 –0.872 –0.085
Cognitive functioning T2 –0.565* 0.176 0.012 –1.020 –0.111
Social functioning T1 Social functioning T2 –0.043 0.194 0.995 –0.544 0.457
Social functioning T3 0.391 0.163 0.074 –0.030 0.813
Functional scales T3 Functional scales T1 –2.435* 0.757 0.012 –4.389 –0.480
Functional scales T2 –2.913* 0.994 0.023 –5.481 –0.345
Insomnia T1 Insomnia T2 0.087 0.188 0.956 –0.398 0.572
Insomnia T3 0.391 0.163 0.074 –0.030 0.813
Constipation T1 Constipation T2 0.174 0.120 0.411 –0.136 0.484
Constipation T3 0.304* 0.117 0.047 0.003 0.605
Symptoms scale T1 Symptoms scale T2 0.391 0.821 0.953 –1.731 2.514
Symptoms scale T3 1.739* 0.488 0.005 0.479 3.000
Based on the least squares means
CI confidence interval, SD standard deviation, T1, T2, T3 times of evaluation (9, 21 and 30 months after radiotherapy)
*The difference in a significant level 0.05
5.747 with GGc; p < 0.01; eta2 = 0.207; Tab. 3). Among
25 prostate cancer-specific medical issues, five variances
were reported to be significant: “urinating frequently at
night” (F[2.42] = 5.370 with GGc; p < 0.05; eta2 = 0.204),
“hurrying to get to the toilet” (F[2.42] = 4.177; p < 0.05;
eta2 = 0.166), “not getting enough sleep because of the
need to get up frequently at night to urinate” (F[2.42] =
3.249 with GGc; p < 0.05; eta2 = 0.134), “difficulty in go-
ing out of the house because of the need to be near a toilet”
(F[2.42] = 5.332 with GGc; p < 0.05; eta2 = 0.202), and
“hot flushes” (F[2.42] = 5.332 with GGc; p < 0.05; eta2 =
0.202).
Discussion
Hypofractionated SBRT is a novel technique for the treat-
ment of early-stage prostate cancer. Preliminary data have
shown that this approach leads to successful tumor control
without increasing complications [25–27].
Acute urinary and rectal toxicities during and after SBRT
are not higher than those for 3D-CRT and IMRT. Collins
et al. [12] reported the good outcome of 232 patients
with both early and advanced disease who were treated
with 36 Gy in 6 fractions. Soete et al. [28] reported
no grade III or IV acute toxicity among 36 prostate can-
cer patients treated with 56 Gy in 16 fractions. King
et al. [26], on behalf of the Multi-institutional Consor-
tium of Prospective Trials, presented an analysis of 864 pa-
tients from phase II clinical trials of SBRT (median dose
of 36.25 Gy in 4–5 fractions) for localized prostate can-
cer (median follow-up of 3 years; 194 patients remained
evaluable at 5 years). Some problems with the bladder and
rectum were observed within the first 3 months after SBRT,
but the conditions returned to baseline status or better within
6 months.
In the current study, 42 % of patients showed no treat-
ment-related reaction during the radiotherapy schedules.
There were no grade III or IV toxicities in the rectum,
and only one patient (1.5 %) developed grade III toxicity in
the bladder. Similarly, in the SHARP study [19], only one
acute grade III genitourinary toxicity during treatment was
reported (2.5 %). In the present study, 31 % of the patients
had no bladder reaction, compared with up to 49 % in the
SHARP trial. Furthermore, in the SHARP trial, 61 % of the
patients had no acute (during and 1 month after the end of
treatment) gastrointestinal toxicity, whereas this value was
63.5 % in our study. The late toxicity result in our study
was similar to that in the SHARP trial: no grade III or
higher late gastrointestinal or genitourinary toxicities were
reported. No late genitourinary toxicity was developed by
55 % of the patients in the SHARP trial and 47 % in our
study. Late gastrointestinal toxicity was even rarer, with
62.5 % of the patients in the SHARP trial and 78 % in our
study not developing such toxicity. There were no grade III
rectal reactions either in the SHARP trial or in our study.
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The King et al. series [29], with a median follow-up of
2.7 years, reported no grade III or higher rectal toxicity and
no grade IV urinary toxicity; only 3.5 % of the patients de-
veloped grade III urinary toxicity (36.25 Gy in 5 fractions).
Yarbro and Ferrans [30] demonstrated that radiotherapy
has little impact on deterioration of QoL. Our research con-
firms that QoL of prostate cancer patients undergoing SBRT
is at a satisfactory level. We observed that the GHS/QoL of
the patients was good 9 months after the end of treatment
and significantly improved during the following months.
Functional aspects, such as physical, emotional, cognitive,
social, and general functioning, also improved.
The American Society for Therapeutic Radiation and
Oncology (ASTRO) definition of biochemical PSA failure
as a surrogate endpoint for recurrence is three consecu-
tive increases in the PSA level after the posttreatment PSA
nadir dated at the midpoint between the nadir and the first
increase [31]. The RTOG Phoenix definition consists of
a PSA level that increases to more than 2.0 ng/mL from the
nadir. As a potential surrogate endpoint in clinical trials,
the Phoenix definition of PSA failure is a strong correlate
of mortality and a predictor of metastatic disease; it is supe-
rior to the ASTRO definition [32]. The 2-year survival rate
without PSA failure ranges from 90 to 100 % [33]. Thus
far, only one observation of patients treated with SBRT has
been performed, with a median follow-up of 5 years [34]:
the biochemical progression-free survival rate was 93 % in
a cohort of 41 consecutive patients (35 or 36.25 Gy in
5 fractions); the median PSA nadir was 0.3 ng/mL. Mad-
sen et al. [35], who applied the same fractionation schedule,
found that the majority of nadirs were less than 1.0 ng/mL.
In our study, the median PSA nadir for patients without
hormone treatment was 0.6 ng/mL. At a median 24-month
follow-up, there were no patients with PSA failure. For
2 patients, the PSA level increased by over 1 ng/mL from
the nadir; for 15 patients, the increase was 0.2–1.0 ng/mL
from the nadir (25 % of all patients). King et al. [36] ob-
served an increase in PSA level of > 0.2 ng/mL in 16 % of
patients at a median 36-month follow-up.
There is more information about the CyberKnife (Accu-
ray, Sunnyvale, CA, USA) than linear accelerator (LINAC)
use for SBRT of prostate cancer patients. Our study used
a LINAC, and all our results (acute and late toxicities, QoL,
and PSA increase and failure) are similar to those obtained
with the CyberKnife series.
One of the potential benefits of SBRT is a short treat-
ment period and probably lower costs compared with other
advanced techniques. Sher at al. [37] showed that SBRT
is a more cost-effective (in terms of radiotherapy, treatment
of acute and late toxicities, and quality-adjusted life year)
external beam modality than IMRT.
Our data are preliminary, as the number of treated pa-
tients is relatively small and follow-up should be longer. In
the intermediate risk-group patients treated with hormonal
therapy, the potential curative effect of radiotherapy cannot
be assessed reliably during hormonal treatment; therefore
the efficacy of SBRT in our patients could not be estimated
precisely and further follow-up is necessary. Follow-up
is planned for 10 years and will be presented in the future.
One of the potential shortcomings was lack of the pre-study
QoL assessment; however we believe that QoL measured
thrice after treatment is informative.
Conclusions
Hypofractionated stereotactic radiotherapy for low- and in-
termediate-risk prostate cancer patients is a safe and con-
venient treatment in terms of its duration, PSA response,
toxicity and patients’ QoL assessment in the short term.
However, a longer follow-up is needed.
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